3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
UNKNOWN
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
402
Triple Negative Breast Neoplasms
64
Neoplasm Metastasis
50
Neoplasms
19
Breast Neoplasms, Male
14
Colorectal Neoplasms
13
Brain Neoplasms
13
Stomach Neoplasms
11
Pancreatic Neoplasms
11
Colonic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Inflammatory Breast Neoplasms
6
HER2-positive Breast Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Advanced Breast Cancer
5
Rectal Neoplasms
4
HER2 Positive Metastatic Breast Cancer
4
Breast Cancer Metastatic
4
Sarcoma
3
Prostatic Neoplasms
3
Meningeal Neoplasms
3
Lymphoma, Non-Hodgkin
3
Gallbladder Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Unknown Primary
2
Interventions
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
selpercatinib
2
exemestane
2
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Docetaxel
2
AZD9833
2
tucatinib
1
ipatasertib
1
glutathione pegylated liposomal doxorubicin
1
entinostat
1
elacestrant
1
atezolizumab
1
alectinib
1
Zoledronic Acid
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
Sodium Chloride
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Imlunestrant
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Capecitabine
×
Breast
×
Clear all
NCT01917279
2020-07-23
CAMELLIA
ChineseAMS
Phase 3
Unknown
280 enrolled